Prespecified secondary analysis of the phase II VOLFI trial in untreated RAS wild-type metastatic colorectal cancer (77 analysed): mFOLFOXIRI + panitumumab vs FOLFOXIRI showed no significant difference in quality of life at baseline or 12 weeks.
Secondary analysisn = 105
Klingler et al. Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial